(19)
(11) EP 2 992 903 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.06.2022 Bulletin 2022/23

(45) Mention of the grant of the patent:
15.07.2020 Bulletin 2020/29

(21) Application number: 15188944.1

(22) Date of filing: 29.09.2011
(51) International Patent Classification (IPC): 
A61K 47/60(2017.01)
A61P 39/00(2006.01)
A61K 45/06(2006.01)
C07D 489/04(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 489/04; A61K 47/60; C07B 2200/13; A61P 25/00; A61P 25/04; A61P 39/00

(54)

COMBINATION OF A NALOXOL-PEG CONJUGATE AND AN OPIOID AGONIST

KOMBINATION VON EINEM NALOXOL-PEG-KONJUGATE UND EINEM OPIOIDAGONIST

COMBINAISON D'UN CONJUGUÉ NALOXOL-PEG AVEC UN AGONISTE OPIOÏDE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 30.09.2010 US 388501 P

(43) Date of publication of application:
09.03.2016 Bulletin 2016/10

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11829686.2 / 2621496

(73) Proprietors:
  • AstraZeneca AB
    151 85 Södertälje (SE)
  • Nektar Therapeutics
    San Francisco, CA 94158 (US)

(72) Inventors:
  • ASLUND, Bengt Leonard
    151 85 Södertälje (SE)
  • AURELL, Carl-Johan
    151 85 Södertälje (SE)
  • BOHLIN, Martin Hans
    151 85 Södertälje (SE)
  • SEBHATU, Tesfai
    151 85 Södertälje (SE)
  • YMEN, Bo Ingvar
    151 85 Södertälje (SE)
  • HEALY, Eric Thomas
    San Francisco, CA 94158 (US)
  • JENSEN, David Richard
    San Francisco, CA 94158 (US)
  • JONAITIS, David Thomas
    West Lafayette, IN 47906-1076 (US)
  • PARENT, Stephan
    West Lafayette, IN 47906-1076 (US)
  • LECHUGA-BALLESTEROS, David
    San Jose, CA 95124 (US)

(74) Representative: Boult Wade Tennant LLP 
Salisbury Square House 8 Salisbury Square
London EC4Y 8AP
London EC4Y 8AP (GB)


(56) References cited: : 
WO-A1-2009/137086
WO-A2-2008/057579
WO-A2-2005/058367
   
  • NEUMANN THERESA A ET AL: "Evaluation of single oral doses of NKTR118 (PEG-naloxol) as a peripheral opioid antagonist (POA): A double-blind placebo-controlled study in healthy male subjects", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 9, 118, 1 September 2007 (2007-09-01), page 1210, XP009120642, ISSN: 0091-2700
  • ODINEES A ET AL: "NKTR-118, AN ORAL PERIPHERAL OPIOID ANTAGONIST, HAS LOW POTENTIAL FOR DRUG-DRUG INTERACTIONS", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 49, no. 9, 141, September 2009 (2009-09), page 1123, XP009120650, & 38TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-CLINICAL-PHARMACOLOGY; SAN ANTONIO, TX, USA; SEPTEMBER 13 -15, 2009 ISSN: 0091-2700 Retrieved from the Internet: URL:http://onlinelibrary.wiley.com/doi/10. 1177/00912700090490091001/pdf>
  • NEUMANN T A ET AL: "Clinical investigation of NKTR-118 as a selective oral peripheral opioid antagonist", POSTER PRESENTED AT THE ANNUAL CLINICAL MEETING OF THE AMERICAN ACADEMY OF PAIN MANAGEMENT ; SEPTEMBER 27-30, 2007; LAS VEGAS, NV,, 27 September 2007 (2007-09-27), page POSTER27, XP001586734,
  • ELDON M A ET AL: "NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone; demonstration of selective peripheral opioid antagonism after oral administration in preclinical models", POSTER PRESENTED AT THE ANNUAL CLINICAL MEETING OF THE AMERICAN ACADEMY OF PAIN MANAGEMENT ; SEPTEMBER 27-30, 2007; LAS VEGAS, NV,, [Online] 27 September 2007 (2007-09-27), page POSTER28, XP001586735, Retrieved from the Internet: URL:http://www.nektar.com>
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).